

# THE MYELOYDYSPLASTIC SYNDROME AND PRELEUKEMIA

ESSAY

Submitted in Partial Fulfilment of  
Master Degree In Clinical Pathology

Presented by

*Anan Becheer Abou El Nasr*

M.B., B.Ch.

Ain Shams University

1984




Under Supervision of

*Prof. Dr. Salwa M. Youssef*

Professor of Clinical Pathology

Faculty of Medicine

Ain Shams University



*Dr. Salwa M. Abou El Hana*

Lecturer of Clinical Pathology

Faculty of Medicine

Ain Shams University

عبد السلام  
سلوى م. أبو هانا  
مناجى حواس

616.075

E.B

FACULTY OF MEDICINE  
AIN SHAMS UNIVERSITY

1991

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَنَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْحَكِيمُ .

صَدَقَ اللَّهُ الْعَظِيمُ

سورة البقرة آية ٣٢



***TO MY FAMILY  
WITH ALL MY LOVE***

## ACKNOWLEDGEMENT

- I am always so grateful to God who helps me.
- It gives me great pleasure to express my deep gratitude and respect to *Prof. Dr. Salwa Mohammed Youssef*, Prof. of Clinical Pathology, faculty of Medicine, Ain Shams University, for her kind advice, generous help and remarkable continuous encouragement throughout the entire work.
- I would also like to offer my appreciation to *Dr. Salwa Mohammed Abou El Hana*, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her supervision, eminent guidance and support for the completion of this work.
- To all my colleagues who kindly gave me a hand to achieve this work, I owe them my deepest thanks.

Anan Beecher

1991

## LIST OF ABBREVIATIONS

AIDS	: Acquired immune deficiency syndrome.
AISA	: Acquired idiopathic sideroblastic anaemia.
AL	: Acute leukemia.
ALIP	: Abnormal localization of immature precursors.
AML	: Acute myeloid leukemia.
ANLL	: Acute non lymphocytic leukemia.
bcr	: break point cluster region.
BFU-E	: Burst forming unit - Erythroid.
BM	: Bone marrow.
CD	: Cluster of differentiation.
CFU-E	: Colony forming unit - Erythroid.
CFU-GEMM	: Colony forming unit - Granulocytic, Erythroid, Monocytic, Macrophage.
CFU-GM	: Colony forming unit - Granulocyte monocyte.
CFU-Meg	: Colony forming unit - Megakaryocyte.
chr	: Chromosome.
CMML	: Chronic myelomonocytic leukemia.
CML	: Chronic myeloid leukemia.
CSA	: Colony stimulating activity.
CSF	: Colony stimulating factor.
DNA	: Desoxyribonucleic acid.
FAB	: French - American - British Cooperative Group.
GM-CFC	: Granulocyte/ macrophage - colony forming cells.

GM-CSF : Granulocyte monocyte colony stimulating factor.

HbF : Faetal hemoglobin.

inv : inversion.

I.V. : Intravenously.

LDAC : low dose cytosine arabinoside.

M-CSF : macrophage colony stimulating factor.

MCV : Mean cell volume.

MDS : Myelodysplastic syndrome.

2°MDS/AL : Secondary MDS/AL.

MOPP : Nitrogen Mustard - Oncovin - Prednisone and  
Procarbazine.

N/C : Nuclear/ cytoplasmic.

NHLs : Non Hodgkin lymphomas.

P : Short arm of chromosome.

P.B. : Peripheral blood.

ph<sup>1</sup> : philadelphia chromosome.

PK : Pyruvate kinase.

PL : Preleukemia.

PL/L : Preleukemia/ leukemia.

PLS : Preleukemic syndrome.

5q- : Deletion of long arm of chromosome 5.

RA : Refractory anaemia.

RAS : Refractory anaemia with ring sideroblasts.

RAEB : Refractory anaemia with excess blasts.

RAEBt : Refractory anaemia with excess blasts in transformation

RNA : Ribonucleic acid.

SLE : Systemic lupus erythematosus.

t : Translocation.

WBC : White blood cells.



## C O N T E N T S

	<b>Page</b>
<b>INTRODUCTION AND THE AIM OF THE WORK.....</b>	1
<b>DEFINITION AND HISTORY OF MYELODYSPLASTIC SYNDROME</b>	3
<b>EPIDEMIOLOGY.....</b>	12
<b>ETIOLOGY.....</b>	14
* Genetic Factors.....	14
* Viral Causes.....	15
* Chemicals.....	16
* Therapy Related.....	17
* Ionizing Radiation.....	20
<b>PATHOGENESIS.....</b>	22
<b>CLASSIFICATIONS.....</b>	25
<b>DIAGNOSIS.....</b>	29
* Clinical Features.....	29
- Age and Sex.....	29
- Symptoms and signs.....	29
- Special clinical features.....	31
* General Morphological and Functional Abnormalities.....	32
- Dyserythropoiesis.....	32
- Dysgranulopoiesis.....	37
- Dysmegakaryopoiesis.....	42
- Immunological abnormalities.....	44
* Specific Features of FAB Types.....	46
* Bone Marrow Histology.....	51
* Cytogenetic studies.....	52
DNA and cell cycle analysis.....	57
* Culture Studies.....	59
* Specific characters of Secondary MDS.....	63
<b>DIFFERENTIAL DIAGNOSIS.....</b>	68
<b>PROGNOSIS.....</b>	72
<b>TREATMENT.....</b>	77
<b>SUMMARY AND CONCLUSION.....</b>	84
<b>REFERENCES.....</b>	88
<b>ARABIC SUMMARY.....</b>	Central Library - Ain Shams University

## ***INTRODUCTION AND AIM OF THE WORK***

## INTRODUCTION AND AIM OF THE WORK

Over the past decade, hematologists have become increasingly aware of patients whose have had refractory cytopenia accompanied by dysplasia of one or more of their hemopoietic cell lineages (*Oscier, 87*).

Although this early observation was confirmed by a number of workers, the concept of preleukemic state was only established in 1953 by Block and Co-workers.

A set of diagnostic criteria of the preleukemic syndrome or hemopoietic dysplasia were established to identify prospectively those patients with a very high likelihood of developing acute myeloid leukemia (*Brennan and Lichtman, 1990*).

In 1982, the FAB group (*Bennett et al., 1982*) introduced proposals for the classification of the myelodysplastic syndrome (MDS) and defined five groups:

- 1- Refractory anaemia (RA).
- 2- Refractory anaemia with ring sideroblasts (RAS).
- 3- Refractory anaemia with excess blasts (RAEB).
- 4- Refractory anaemia with excess blasts in transformation (RAEBt).
- 5- Chronic myelomonocytic leukemia (CMML).

The aim of this study is to identify precisely myelodysplastic syndrome as regards: Classifications, pathogenesis, clinical variaties, heamatological findings, cytogenetic study, prognosis and treatment.

# ***REVIEW OF LITERATURE***

## **MYELOYDYSPLASTIC SYNDROME AND PRELEUKEMIA**

### **DEFINITION:**

Myelodysplastic syndrome (MDS) and preleukemic syndrome (PLS) are synonymous for a group of clonal proliferative disorders of the bone marrow that are characterized by dysmyelopoiesis and peripheral blood cytopenias. These disorders may progress to overt acute non lymphocytic leukemia (ANLL) or cause death of the patient secondary to complication of ineffective hematopoiesis (*Pierre, 1986*).

### **HISTORY AND NOMENCLATURE:**

Patients who would now be recognized as having MDS have been described since the turn of this century, but evaluation of early reports is hindered by the fact that different haematologists have emphasized particular aspects of the condition and a confusing nomenclature has arisen, with some terms being synonymous and others reflecting different phases in the natural history of MDS (*Oscier, 1987*).

In the 1930s there was much interest in patients with anaemias which were refractory to haematinics such as iron, vitamin B<sub>12</sub> and folic acid.. *Rhoads and Barker (1938)*

described 100 cases of refractory anaemia some were associated with and secondary to other diseases, while others were thought to be primary haematological disorders. this anaemia was often associated with leucopenia and thrombocytopenia.

Chevallier - in 1942 discussed the "odo-leukemias". He chose the Greek word odo, meaning threshold, to highlight disorders that are on the threshold of leukemia.

*Hamilton-Paterson (1949)* described three patients who presented with refractory anaemia and subsequently developed acute myeloid leukemia. Seven years later *Bjorkman (1956)* delineated a subgroup of refractory anaemia characterized by the presence of ring sideroblasts in the marrow, and one of his four cases evolved into acute myeloid leukemia (AML).

In the 1950s and early 60s there was an increasing awareness of elderly patients with a modest increase in blast cells in the marrow in association with a peripheral cytopenia, whose illness pursued a chronic course before terminating in acute leukemia (AL). This condition was variously described as preleukemic acute human leukemia (*Block et al., 1953*), low percentage leukemia (*Dameshek & Gunz, 1958*) and smouldering acute leukemia (*Rheingold et al., 1963*).